Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection

Sexually Transmitted Infections

Volumn 74, Issue 5, 1998, Pages 354-360

  Van Doornum, Gerard ^a   Prins, Maria ^a   Andersson Ellström, Agneta ^b   Dillner, Joakim ^c  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b Centre for Public Health Research Karlstad   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Capsids; Human papillomavirus; Immunoglobulins

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS DNA;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS CAPSID; VIRUS STRAIN; WART VIRUS;

EID: 0031667883     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.74.5.354     Document Type: Article

References (36)

1. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
2. Evander M, Edlund K, Gustafsson Ä, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995;171: 1026-30.
3. Dillner J. Serology of human papillomavirus. Cancer J 1995; 8:264-9.
4. Galloway DA. HPV serology: an update. In: Lacey C, ed. Papilloma reviews: current research on papillomaviruses. Leeds: Leeds Medical Information, 1996;113-19.
5. Van Doornum GJJ, Prins M, Pronk L, et al. A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. J Clin Diagn Lab Immunol 1994;1:633-9.
6. Andersson-Ellström A, Dillner J, Hagmar BM, et al. Comparison of development of serum antibodies to HPV 16 and HPV 33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234-8.
7. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
8. Chua K-L, Wiklund F, Lenner P, et al. A prospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996;68:54-9.
9. Dillner J, Kallings I, Brihmer C, et al. Seropositivity to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis 1996;173:1394-8.
10. Kirnbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-8.
11. Lowy DR, Kirnbauer R, Schiller JT. Genital human papillomavirus infection. Proc Natl Acad Sci USA 1994;91:2436-40.
12. Wideroff L, Schiffman MH, Nonnemacher B, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-30.
13. Wideroff L, Schiffmann MH, Hoover R, et al. Epidemiological determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women. J Infect Dis 1996;174: 937-43.
14. Wikström A, Van Doornum GJJ, Kirnbauer R, et al. Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condylomata acuminata or new asymptomatic infection. J Med Virol 1995;46:368-74.
15. Dillner J, Knekt P, Schiller JT, et al. Prospective seroepidemiological evidence that human papilloma-virus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ 1995;311:1346.
16. Heino P, Eklund C, Frederiksson-Shahnazarian V, et al. Association of serum antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995;87:437-40.
17. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma. BMJ 1996;312:537-9.
18. Nonnenmacher B, Hubbert NL, Kirnbauer R, et al. Serologic responses to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Columbia and Spain. J Infect Dis 1995;172:19-24.
19. Nonnenmacher B, Kruger Kjaer S, Svare EI, et al. Seroreactivity to HPV 16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer 1996;68: 704-9.
20. Andersson-Ellström A, Hagmar BM, Johansson B, et al. Human papillomavirus deoxyribonucleic acid in cervix only detected in girls after coitus. Int J STD AIDS 1996;7: 333-6.
21. Carter JJ, Wipf GC, Hagensee ME, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11-18.
22. Wikström A, Van Doornum GJJ, Schiller JT, et al. Identification of HPV seroconversions. J Gen Virol 1995;76:529-39.
23. Skyldberg B, Kalantari M, Karki M, et al. Detection of human papillomavirus infection in tissue blocks by in situ hybridization as compared with a polymerase chain reaction procedure. Human Pathol 1991;22:578-82.
24. Skyldberg B, Hagmar B, Johansson B, et al. HPV detection in cytological cases with condylomatous or dysplastic changes. A study with PCR and in situ hybridization on cytologic material. Diag Cytopathol 1995;13:8-14.
25. Manos MM, Ting Y, Wright DK, et al. Use of polymerase chain reaction amplification for the detection of human papillomaviruses. Cancer Cells 1989;7:209-21.
26. Van Doornum GJJ, Prins M, Juffermans LHJ, et al. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple partners: a prospective study. Genitourin Med 1994;70:240-7.
27. Claas ECJ, Melchers WJG, Van der Linden HC, et al. Human papillomavirus detection in paraffin embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. Am J Pathol 1989;135:703-9.
28. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
29. Volpers C, Schirmacher P, Streck RE, et al. Assembly of the major and minor capsid proteins of HPV type 33 into virus-like particles and tubular structures in insect cells. Virology 1994;200:504-12.
30. Norusis WJ. SPSS/PC+4.0. Chicago: SPSS, 1990.
31. Heim K, Christensen ND, Hoepfl R, et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynaecologic patient groups. J Infect Dis 1995;175:395-402.
32. Olsen AO, Dillner J, Gjøen K, et al. Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med 1997;73:131-5.
33. Van Belkum A, Juffermans L, Schrauwen L, et al. Genotyping human papillomavirus type 16 isolates from persistently infected promiscuous individuals and cervical neoplasia patients. J Clin Microbiol 1995;33:2957-62.
34. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological responses to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.
35. Eisemann C, Fisher SG, Gross G, et al. Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. J Gen Virol 1996;77:1799-803.
36. Svare EI, Krüger-Kjaer S, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high risk men than in high-risk women. J Infect Dis 1997;76:876-83.